© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
February 01, 2015
Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
April 23, 2014
The RAS-RAF-MEK-extracellular signalâ€“regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.
August 22, 2013
Alex A. Adjei, MD, PhD, discusses the use of MEK inhibitors when treating patients with melanoma.